Thiocarbazones Or Thiosemicarbazones (i.e., C=n-n-c(=s)-n Containing) Patents (Class 514/582)
  • Publication number: 20120294826
    Abstract: The present invention provides, inter alia, methods for ameliorating an adverse effect in a patient caused by an acute transfusion into the patient of a composition containing aged red blood cells using an iron chelator. Apparatuses and kits for ameliorating such adverse effects are also provided.
    Type: Application
    Filed: December 1, 2011
    Publication date: November 22, 2012
    Inventors: Steven L. Spitalnik, Eldad A. Hod, Gary M. Brittenham
  • Publication number: 20120276121
    Abstract: The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.
    Type: Application
    Filed: July 13, 2012
    Publication date: November 1, 2012
    Applicants: INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA, CENIX BIOSCIENCE GMBH
    Inventors: MICHAEL HANNUS, CECILIE MARTIN, MARIA M. MOTA, MIGUEL PRUDENCIO, CHRISTINA DIAS RODRIGUES
  • Publication number: 20110305632
    Abstract: The present invention relates to a method of making asymmetrical bis(thiosemicarbazones), compounds useful as synthetic intermediates in the method, new bis(thiosemicarbazones) that can be readily accessed by use of the method and methods of treatment and imaging utilising some of the new bis(thiosemicarbazones).
    Type: Application
    Filed: December 11, 2009
    Publication date: December 15, 2011
    Applicant: THE UNIVERSITY OF MELBOURNE
    Inventors: Paul Stephen Donnelly, Brett Michael Paterson
  • Patent number: 7893108
    Abstract: Disclosed herein are antiviral compounds, such as anti-human cytomegalovirus antiviral compounds, pharmaceutical compositions and antiviral methods.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: February 22, 2011
    Assignee: President and Fellows of Harvard College
    Inventors: Donald M. Coen, Arianna Loregian
  • Patent number: 7820656
    Abstract: Disclosed is a medicament comprising N-aryl N? morpholino/piperidino thiocarbamide derivatives represented by the following formula 1 for preventing and treating diabetes, diabetic complications, insulin resistance and insulin resistance syndrome, and can be used in drugs, foods, and beverages inducing an effect of preventing and treating diabetes, diabetic complications, insulin resistance and insulin resistance syndrome of modern people who suffer from the increasing development of diabetes resulting from environmental factors, such as intake of westernized foods, obesity, and so on: wherein, X is O or C, and R represents 4-chlorophenyl, 2-methylphenyl, 3-methoxypheny, 3-methylphenyl, or phenyl group.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: October 26, 2010
    Inventor: Sung-Jin Kim
  • Patent number: 7521062
    Abstract: The present invention is directed to novel immune potentiators, novel vaccine adjuvants, novel compounds and pharmaceutical compositions, novel methods for treating viral infections, including HCV, by administering the compounds, and novel methods for modulating an immune response by administering the compounds.
    Type: Grant
    Filed: December 29, 2003
    Date of Patent: April 21, 2009
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Paul A. Barsanti, Nathan Brammeier, Anthony Diebes, Liana Marie Lagniton, Simon Ng, Zhi-Jie Ni, Keith B. Pfister, Casey Philbin, Nicholas Valiante, Allan S. Wagman, Weibo Wang, Amy J. Weiner
  • Publication number: 20090042870
    Abstract: An antimicrobial composition suitable for cleaning inanimate surfaces and human skin comprises two or more cationic biocides and two or more biocides which are slower acting than the cationic biocides, wherein each cationic biocide is independently either: (i) a quaternary ammonium compound at a concentration of at least 0.1% w/v; or (ii) a biguanide compound.
    Type: Application
    Filed: March 20, 2006
    Publication date: February 12, 2009
    Inventors: Adrian Fellows, Guy Braverman, Allen Hanouka
  • Patent number: 6911460
    Abstract: The present invention relates to methods of treating viral or fungal infections using 3-aminopyridine-2-carboxyaldehyde thiosemicarbazone (3-AP) and 3-amino-4-methylpyridine-2-carboxaldehyde thiosemicarbazone (3-AMP) and its prodrug forms and to pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: June 28, 2005
    Assignees: Vion Pharmaceuticals, Inc., Yale University
    Inventors: Ivan C. King, Terrance W. Doyle, Mario Sznol, Alan C. Sartorelli, Yung-Chi Cheng
  • Patent number: 6897240
    Abstract: The present invention relates to thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of using such compounds to prevent and treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis. The compounds also find use in inhibiting cysteine proteases associated with carcinogenesis, including cathepsins B and L.
    Type: Grant
    Filed: May 8, 2003
    Date of Patent: May 24, 2005
    Assignee: The Regents of the University of California
    Inventors: Fred E. Cohen, Xiaohui Du, Chun Guo, James H. McKerrow
  • Publication number: 20040014801
    Abstract: The present invention relates to thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of using such compounds to prevent and treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis. The compounds also find use in inhibiting cysteine proteases associated with carcinogenesis, including cathepsins B and L.
    Type: Application
    Filed: May 8, 2003
    Publication date: January 22, 2004
    Applicant: The Regents of the University of California
    Inventors: Fred E. Cohen, Xiaohui Du, Chun Guo, James H. McKerrow
  • Publication number: 20030176503
    Abstract: Thiosemicarbazone compounds of formula: 1
    Type: Application
    Filed: April 19, 2002
    Publication date: September 18, 2003
    Inventors: Sergio Altamura, Uwe Koch
  • Patent number: 6620806
    Abstract: The present invention provides methods and kits for improving or maintaining vascular health, including preventing myocardial infarction or stroke; maintaining or improving vascular reactivity; treating acute or chronic renal failure, peripheral arterial occlusive disease, coronary artery disease, or Raynaud's phenomenon; or lowering plasma levels of Lp(a) using an estrogen agonist/antagonist.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: September 16, 2003
    Assignee: Pfizer Inc.
    Inventors: Wesley W. Day, Andrew G. Lee, David D. Thompson
  • Patent number: 6566375
    Abstract: Compounds of this invention increase plasma levels of high density lipoprotein or HDL, the “good” cholesterol and as such may be useful for treating diseases such as atherosclerosis.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: May 20, 2003
    Assignee: Wyeth
    Inventor: Thomas J. Commons
  • Publication number: 20030045581
    Abstract: The present invention is directed to optionally substituted 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs thereof, represented by the Formulae I and II: 1
    Type: Application
    Filed: June 3, 2002
    Publication date: March 6, 2003
    Inventors: Sui Xiong Cai, Bao Ngoc Nguyen, John Drewe, P. Sanjeeva Reddy, Shailaja Kasibhatla, Azra Pervin
  • Publication number: 20020183321
    Abstract: This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by Formula I: 1
    Type: Application
    Filed: June 25, 2002
    Publication date: December 5, 2002
    Inventors: Yan Wang, Sui Xiong Cai, Nancy C. Lan, John F.W. Keana, Victor I. Ilyin
  • Patent number: 6034102
    Abstract: A method of treating atherosclerosis, independent of lipid lowering, in mammals, including humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque. Such lesion progression inhibition or plaque stabilization is preferably achieved by directly inhibiting chemokine expression leading to excessive inflammatory cell recruitment by administering a therapeutically effective amount of a compound of formula I.
    Type: Grant
    Filed: October 21, 1997
    Date of Patent: March 7, 2000
    Assignee: Pfizer Inc
    Inventor: Robert J. Aiello
  • Patent number: 5573747
    Abstract: A method of preparing a radiopharmaceutical in a form suitable for intravenous bolus injection is disclosed. The method comprises eluting .sup.62 Cu from from an anion exchange column loaded with .sup.62 Zn.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: November 12, 1996
    Inventor: Jeffrey L. Lacy
  • Patent number: 5571843
    Abstract: Therapeutic compounds having the formula: ##STR1## in which R.sub.2 and R.sub.3 independently denote H, C.sub.1 -C.sub.4 alkoxy or OH and (A, B)=(oxygen, oxygen) in which case one out of R and R.sub.1 denotes OH, halogen, secondary amino or tertiary amine and the other denotes NHNHCONHR.sub.4 or R and R.sub.1 together denote .dbd.N--NH--CX--NHR.sub.5, .dbd.N--NH--CX--N(phenyl).sub.2, .dbd.N--NH--CX--NH--NH--R.sub.5, .dbd.N--NH--C(SCH.sub.3).dbd.N--R.sub.6 or .dbd.N--N.dbd.C(SCH.sub.3)--NH--R.sub.6 ; or (A, B)=(N--OH, oxygen) in which case R and R.sub.1 together form .dbd.N--NH--CX--NHR.sub.5 or .dbd.N--NH--CX--N(phenyl).sub.2 ; or (A, B)=(N--NH--CX--NHR.sub.5, oxygen) in which case R and R.sub.1 together form .dbd.N--NH--CX--NHR.sub.5 ; or (A, B)=(N--OH, N--OH) in which case R and R.sub.1 together form .dbd.N--NH--CX--NHR.sub.5 or .dbd.N--NH--CX--N(phenyl).sub.2.
    Type: Grant
    Filed: March 24, 1994
    Date of Patent: November 5, 1996
    Assignee: Innothera
    Inventors: Michel P. Cugnon de Sevricourt, Catherine G. Dacquet, Michel A. Finet, Florence J. Le Marquer, Max F. Robba, Norbert O. Tembo, Sylvie J. Yannic-Arnoult, Jean-Luc Torregrosa
  • Patent number: 5461076
    Abstract: Compounds of formula I ##STR1## wherein A, X, Z and R.sub.1 -R.sub.5 are as defined in the description, and their salts have valuable pharmaceutical properties and are effective especially against tumors. They are prepared in a manner known per se.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: October 24, 1995
    Inventors: Jaroslav Stanek, Jorg Frei, Giorgio Caravatti
  • Patent number: 5395855
    Abstract: Compounds of formula I ##STR1## wherein A, X, Z and R.sub.1 -R.sub.5 are as defined in the description, and their salts have valuable pharmaceutical properties and are effective especially against tumors. They are prepared in a manner known per se.
    Type: Grant
    Filed: March 28, 1994
    Date of Patent: March 7, 1995
    Assignee: Ciba-Geigy Corporation
    Inventors: Jaroslav Stanek, Jorg Frei, Giorgio Caravatti
  • Patent number: 5281597
    Abstract: This invention is directed to heterocyclic and aromatic thiosemicarbazones seful in the treatment of filariasis and in an animal, including humans.
    Type: Grant
    Filed: November 8, 1991
    Date of Patent: January 25, 1994
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: John W. McCall, Daniel L. Klayman, Ai Jeng Lin, Kenneth E. Kinnamon, Max Grogl
  • Patent number: 5238933
    Abstract: Skin permeation enhancer compositions are provided which increase the permeability of skin to transdermally administered pharmacologically active agents. The compositions contain a lower aliphatic ester of a lower aliphatic carboxylic acid such as ethyl acetate and a lower alkanol such as propylene glycol. Methods and transdermal drug delivery systems for using the compositions are also provided.
    Type: Grant
    Filed: April 2, 1992
    Date of Patent: August 24, 1993
    Assignee: SRI International
    Inventors: Paul G. Catz, David R. Friend, Harold W. Nolen, III
  • Patent number: 5104875
    Abstract: Pharmaceutical combination preparations containing rifampicin and thioacetazon and optionally isonicotinic acid hydrazide or ethambutol and the use of same for the treatment of mycobacterial infections.
    Type: Grant
    Filed: May 15, 1990
    Date of Patent: April 14, 1992
    Assignee: Fatol Arzneimittel GmbH
    Inventors: Klaus Jurgen, Joachim Seydel
  • Patent number: 4607044
    Abstract: Certain organic compounds derived from urea or thiourea having insectical activity and methods of their preparation are disclosed. The compounds according to the invention have been found to interfere with the mechanism of metamorphoses which occurs in insects. Hence the substances according to the invention are specifically active against insects. Owing to this specificity and because of the absence of phytotoxicity effects, the compounds of this invention are of prime importance.
    Type: Grant
    Filed: October 30, 1984
    Date of Patent: August 19, 1986
    Assignee: Duphar International Research B.V.
    Inventors: Kobus Wellinga, Rudolf Mulder